Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Efficacy and safety of intravenous chemotherapy in children with intraocular retinoblastoma

2.

Frontline Decisions in Transplant-Ineligible Multiple Myeloma: Evaluating Quadruplet Therapy

3.

Spicy Chip Death Lawsuit; Gen X and Cancer; Extreme U.S. Temperatures

4.

A global study demonstrates that screening for lung cancer significantly raises the long-term survival rate.

5.

Women who miss their first mammogram face higher risk of breast cancer death, study finds


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot